A Through QT/QTc Study of KW-6356

NCT04342273 | Completed Phase 1

• 1 other identifier: 6356-007
• Study Type: interventional
• Target: 128
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this study is to evaluate the effects of multiple therapeutic and supratherapeutic doses of KW-6356 on the QT interval corrected for heart rate in Japanese healthy adults.

Conditions

Parkinson's Disease

Outcome Measures

Primary Outcomes (1)

• Change from baseline in QTc interval [QTcF] (ΔQTcF)

  Day 1 through Day 7

Secondary Outcomes (16)

• Changes from baseline in the HR

  Day 1 through Day 7

• Changes from baseline in the QTc interval [QTcF]

  Day 1 through Day 7

• Changes from baseline in the PR interval

  Day 1 through Day 7

• Changes from baseline in the QRS interval

  Day 1 through Day 7

• Placebo-corrected ΔQTcF

  Day 1 through Day 7

Study Arms (4)

KW-6356 therapeutic dose

EXPERIMENTAL

Oral administration

Drug: KW-6356

KW-6356 supratherapeutic dose

EXPERIMENTAL

Oral administration

Drug: KW-6356

Placebo

PLACEBO COMPARATOR

Oral administration

Drug: Placebo

Moxifloxacin

ACTIVE COMPARATOR

Oral administration

Drug: Moxifloxacin

Interventions

KW-6356 DRUG

KW-6356 will be administered once daily as therapeutic at Day 1 through Day 7

KW-6356 therapeutic dose

Placebo DRUG

Placebo will be administered once daily at Day 1 through Day 7

Placebo

Moxifloxacin DRUG

Placebo will be administered once daily at Day 1 through Day 6, followed by Moxifloxacin once daily at Day 7.

Moxifloxacin

Eligibility Criteria

• Age: 20 Years - 54 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subjects having issued written consent to this study at their own discretion
• Men or women aged 20 to 54 years at the time of informed consent
• Subjects with BMI ≥18.5 and \<25.0 at screening
• In case of women of childbearing potential,\* subjects who have agreed to use highly effective and appropriate contraceptive methods from the time of informed consent to 4 weeks after the last dose of the investigational product or the index drug. Women of childbearing potential must have a negative serum pregnancy test at screening
• At screening and Day -2, subjects with resting pulse rate of ≥45 and \<100 bpm, systolic blood pressure of ≥90 and \<140 mmHg, and diastolic blood pressure of ≥40 and \<90 mmHg when measured in the supine position
• Subjects whose standard 12-lead ECG data obtained at screening and Day -2 meet the following criteria and show no clinically significant abnormalities as confirmed by the investigator or subinvestigator Normal sinus rhythm: HR of ≥45 and ≤100 bpm QTc interval (QTcF): ≤450 msec QRS interval: ≤120 msec (must be re-measured manually if exceeding 120 msec) PR interval: ≤220 msec
• Subjects whose potassium, sodium, calcium, and magnesium levels at screening are within institutional normal limits

You may not qualify if:

• Subjects with any current disease requiring treatment
• Subjects having drug allergy or its history
• Subjects having psychiatric disease or its history
• Positive results for any of the following infection-related items examined at screening: hepatitis B surface (HBs) antigen, HBs antibody, hepatitis B core (HBc) antibody, hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antigen/antibody, human T-lymphotropic virus (HTLV)-1 antibody, rapid plasma reagin (RPR) test, or Treponema pallidum (TP) antibody
• Subjects being alcohol- or drug-dependent or having a positive result for any of the drug abuse test items
• Subjects previously or concurrently having any of the following diseases or subjects with a family history of any of the following diseases:
• Hypokalemia, hypocalcemia, and/or long QT syndrome Risk factors for torsade de pointes such as cardiac failure, cardiomyopathy, and a family history of long QT syndrome Sick sinus syndrome, second- or third-degree atrioventricular block, myocardial infarction, pulmonary congestion, cardiac arrhythmia, QT interval prolongation, or atrioventricular conduction disturbance Repeated or frequent syncope or vasovagal attack Hypertension, angina pectoris, bradycardia, or severe peripheral arterial circulatory disorder
• Subjects categorized as patients listed in the warnings or contraindications section of the package insert of moxifloxacin hydrochloride
• Subjects unable to be compliant with Specified "Concomitant Medication and Concomitant Therapy" and "Instruction for Subjects"
• Subjects having participated in a clinical study of a pharmaceutical product or a medical device or any equivalent study and used the investigational product or the unapproved medical device within 4 months prior to administration of the investigational product
• Subjects having used any drug within 2 weeks prior to administration of the investigational product
• Subjects having consumed grapefruit or any food or beverage containing St John's wort within 1 week prior to administration of the investigational product
• Subjects having smoked or used smoking cessation agents within 4 weeks prior to administration of the investigational product
• Subjects categorized as "yes" to "active suicidal ideation with some intent to act, without specific plan" or "active suicidal ideation with specific plan and intent" on the Columbia-Suicide Severity Rating Scale assessed on Day -2 or subjects with a history of or currently observed suicidal behavior
• Subjects having undergone ≥400 mL of blood collection within 12 weeks prior to administration of the investigational product or ≥200 mL of blood collection within 4 weeks prior to administration of the investigational product for blood donation or in a clinical trial, etc. or subjects having undergone blood collection for pheresis donation within 2 weeks prior to administration of the investigational product

Sponsors & Collaborators

• Kyowa Kirin Co., Ltd.: lead

Study Sites (2)

Medical Co. LTA Sumida Hospital

Sumida-ku, Tokyo, Japan

Location

Medical Co. LTA Fukuoka Mirai Hospital Clinical Research Center

Fukuoka, Japan

Location

MeSH Terms

Conditions

Parkinson Disease

Interventions

Moxifloxacin

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Intervention Hierarchy (Ancestors)

Fluoroquinolones; 4-Quinolones; Quinolones; Quinolines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 8, 2020
• First Posted: April 13, 2020
• Study Start: March 31, 2020
• Primary Completion: September 5, 2020
• Study Completion: September 5, 2020
• Last Updated: September 18, 2020

Record last verified: 2020-09

Locations

JP (2)